Kayne Anderson Rudnick Investment Management
GBT

Kayne Anderson Rudnick Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-75
Closed -$3K – 699
2022
Q1 		$3K Buy
+75
New +$2.24K ﹤0.01% 589

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's GBT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 75 shares — an estimated $3K sold.

Kayne Anderson Rudnick Investment Management first reported a position in GBT in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 75 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $3K.
  • Kayne Anderson Rudnick Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's Global Blood Therapeutics, Inc. position peaked at $3K in Q1 2022.
  • 195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.